Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 9/20 | 0.66 |
| ▸ | RAB9A | P51151 | 9/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.66 |
| ▸ | NFKB1 | P19838 | 3/20 | 0.66 |
| ▸ | NFKB2 | Q00653 | 3/20 | 0.66 |
| ▸ | RELA | Q04206 | 3/20 | 0.66 |
| ▸ | PKM | P14618 | 2/20 | 0.66 |
| ▸ | MAPT | P10636 | 2/20 | 0.66 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.64 |
| ▸ | CASP3 | P42574 | 4/20 | 0.63 |
| ▸ | SENP7 | Q9BQF6 | 4/20 | 0.63 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.62 |
| ▸ | MEN1 | O00255 | 4/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.59 |
| ▸ | TP53 | P04637 | 2/20 | 0.59 |
| ▸ | HPGD | P15428 | 2/20 | 0.59 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.59 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.59 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31019604 | 1.00 | NPC1 (0.66) | NPC1RAB9ASMN1; SMN2ALDH1A1NFKB1 | |
| SCHEMBL6581336 | 0.89 | KDM4E (0.67) | NPC1RAB9ASMN1; SMN2ALDH1A1NFKB1 | |
| SCHEMBL18101256 | 0.85 | KDM4E (0.64) | NPC1RAB9ASMN1; SMN2ALDH1A1NFKB1 | |
| SCHEMBL18101216 | 0.85 | KDM4E (0.64) | NPC1RAB9ASMN1; SMN2ALDH1A1NFKB1 | |
| SCHEMBL18101260 | 0.85 | KDM4E (0.64) | NPC1RAB9ASMN1; SMN2ALDH1A1NFKB1 | |
| SCHEMBL18101254 | 0.85 | KDM4E (0.64) | NPC1RAB9ASMN1; SMN2ALDH1A1NFKB1 | |
| SCHEMBL18359200 | 0.84 | NPC1 (0.68) | NPC1RAB9ASMN1; SMN2ALDH1A1NFKB1 | |
| SCHEMBL9585897 | 0.82 | RAB9A (0.67) | NPC1RAB9ASMN1; SMN2ALDH1A1NFKB1 | |
| SCHEMBL21165315 | 0.82 | NPC1 (0.66) | NPC1RAB9ASMN1; SMN2ALDH1A1NFKB1 | |
| SCHEMBL5192592 | 0.82 | KMT2A (0.70) | NPC1RAB9ASMN1; SMN2ALDH1A1NFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114989131-B | N' - (2- (benzo [1,3] dioxolan-5-yl) acyl) aryl hydrazide compound as well as synthesis and application thereof | 云南大学 | 2023-10-24 | — | — | CN | claimed |
| CN-114989131-A | N' - (2- (benzo [1,3] dioxolane-5-yl) acyl) aroyl hydrazide compound and synthesis and application thereof | 云南大学 | 2022-09-02 | — | — | CN | claimed |
| US-7091238-B1 | Thienylhydrazon with digitalis-like properties (positive inotropic effects) | UNIVERSITY OF MARYLAND (US) | 2006-08-15 | — | — | US | claimed |
| EP-1532140-A1 | THIENYLHYDRAZON WITH DIGITALIS-LIKE PROPERTIES ( POSITIVE INOTROPIC EFFECTS ) | University of Maryland, Baltimore (US) | 2005-05-25 | — | — | EP | claimed |
| WO-2000078754-A1 | THIENYLHYDRAZON WITH DIGITALIS-LIKE PROPERTIES (POSITIVE INOTROPIC EFFECTS) | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2000-12-28 | — | — | WO | claimed |
| US-20250346588-A1 | IMIDAZOPYRIDINE AND OXAZOLOPYRIDINE DERIVATIVES AND ANALOGS THEREOF, METHODS OF PREPARATION THEREOF, METHODS OF HIF-1/2A PATHWAY INHIBITION, AND INDUCTION OF FERROPTOSIS | KUDA THERAPEUTICS INC (US) | 2025-11-13 | — | — | US | disclosed |
| CN-118619846-A | Application of allylation reagent and preparation method of high-added-value allyl hydrazone | 中国科学院山西煤炭化学研究所 | 2024-09-10 | — | — | CN | disclosed |
| CN-114989131-B | N' - (2- (benzo [1,3] dioxolan-5-yl) acyl) aryl hydrazide compound as well as synthesis and application thereof | 云南大学 | 2023-10-24 | — | — | CN | disclosed |
| US-11584726-B2 | Amino alcohol derivative, pharmaceutical composition and application thereof | BEIJING FORELAND PHARMA CO., LTD. (CN) | 2023-02-21 | — | — | US | disclosed |
| US-11447482-B1 | Imidazopyridine and oxazolopyridine derivatives and analogs thereof, methods of preparation thereof, methods of HIF-2A pathway inhibition, and induction of ferroptosis | KUDA Therapeutics, Inc. (US) | 2022-09-20 | — | — | US | disclosed |
| US-20220281862-A1 | Imidazopyridine and Oxazolopyridine Derivatives and Analogs Thereof, Methods of Preparation Thereof, Methods of HIF-2A Pathway Inhibition, and Induction of Ferroptosis | KUDA Therapeutics, Inc. | 2022-09-08 | — | — | US | disclosed |
| CN-114989131-A | N' - (2- (benzo [1,3] dioxolane-5-yl) acyl) aroyl hydrazide compound and synthesis and application thereof | 云南大学 | 2022-09-02 | — | — | CN | disclosed |
| WO-2002040487-A2 | BENZODIAZEPINE DERIVATIVES AS GABA A RECEPTOR MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-05-23 | — | — | WO | disclosed |
| US-20020002152-A1 | Hydrazide and alkoxyamide angiogenesis inhibitors | ABBOTT LABORATORIES | 2002-01-03 | — | — | US | disclosed |
| US-6265426-B1 | CENTRAL NERVOUS SYSTEM DISORDERS | HOFFMANN-LA ROCHE INC. | 2001-07-24 | — | — | US | disclosed |
| EP-1070708-A1 | Triazole and imidazole derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2001-01-24 | — | — | EP | disclosed |
| WO-2000078754-A1 | THIENYLHYDRAZON WITH DIGITALIS-LIKE PROPERTIES (POSITIVE INOTROPIC EFFECTS) | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2000-12-28 | — | — | WO | disclosed |
| US-5536853-A | Opiate receptor ligands | CHIRON CORPORATION (US) | 1996-07-16 | — | — | US | disclosed |
| WO-1995027729-A1 | OPIATE RECEPTOR LIGANDS | CHIRON CORPORATION (US) | 1995-10-19 | — | — | WO | disclosed |
| US-4456752-A | REACTING A HYDRAZINE WITH DIHALOGEN SUBSTITUTED PYRIDO(1,2-A)PYRIMIDINE | CHINOIN GYOGYSZER ES VEGYESZETI TERMEKEK GYARA R.T. (HU) | 1984-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250346588-A1 | IMIDAZOPYRIDINE AND OXAZOLOPYRIDINE DERIVATIVES AND ANALOGS THEREOF, METHODS OF PREPARATION THEREOF, METHODS OF HIF-1/2A PATHWAY INHIBITION, AND INDUCTION OF FERROPTOSIS | HIF1AN, HIF1A, EGLN2 | NPC1 1895/4885RAB9A 3536/4885SMN1; SMN2 3168/4885 |
| US-11447482-B1 | Imidazopyridine and oxazolopyridine derivatives and analogs thereof, methods of preparation thereof, methods of HIF-2A pathway inhibition, and induction of ferroptosis | HIF1AN, HIF1A, EGLN2 | NPC1 2512/4885RAB9A 3136/4885SMN1; SMN2 3470/4885 |
| US-20220281862-A1 | Imidazopyridine and Oxazolopyridine Derivatives and Analogs Thereof, Methods of Preparation Thereof, Methods of HIF-2A Pathway Inhibition, and Induction of Ferroptosis | HIF1AN, HIF1A, EGLN2 | NPC1 2512/4885RAB9A 3136/4885SMN1; SMN2 3470/4885 |
| US-11584726-B2 | Amino alcohol derivative, pharmaceutical composition and application thereof | SSB, HLA-DRB1, LCP2 | NPC1 4456/4885RAB9A 4057/4885SMN1; SMN2 52/4885 |
| US-20020002152-A1 | Hydrazide and alkoxyamide angiogenesis inhibitors | METAP2, METAP1, ANPEP | NPC1 3808/4885RAB9A 2314/4885SMN1; SMN2 4547/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.